(NewsDirect)
Poolbeg Pharma chairman Cathal Frieljoined Proactive's Stephen Gunnion to discuss his new hands-onrole at the company.
Stepping up asthe executive chairman at Poolbeg Pharma, Friel expressed hisintention to replicate the success he achieved with hVIVO, anothercompany he founded. With the addition of key former Amryt leadershipteam members to Poolbeg, Friel said he is optimistic about thecompany's aggressive growth prospects and is focused on shareprice appreciation.
The chairmanalso explained the rational for the sale of shares in hVIVO PLC bydirectors, including himself.
Friel,who has a rich background in mergers and acquisitions (M&A) andinvestment banking, said the decision was driven by stronginstitutional demand for hVIVO stock. Despite selling a small portionof his stake, he affirmed his long-term commitment to the company,highlighting its robust growth, profitability, and cash generationunder current management.
He alsorevealed plans to increase his stake in Poolbeg, indicating confidencein the company's potential and his commitment to drivingshareholder value.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2024 TheNewswire - All rights reserved.